Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab and cemdisiran combination after pozelimab monotherapy in PNH
2020-005005-17Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pozelimab and cemdisiran in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Mar 2021; status: completed.
02
Drugs
pozelimabcemdisiran
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2020-005005-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005005-17.